Collectively, our results demonstrate that miR-148b-5p deficiency-mediated development of GC is partially attributed to the aberrant reprogramming in metabolism and tumor immunity microenvironment in GC, and that the miR-148b-5p/ATPIF1/TNFa plus IL6 and CSF1 axis establishes the groundwork to further develop more-personalized therapeutic methods for GC patients. The gene discussed is CSF1; the disease is gastric cancer.